Arna Pharma, Slate Run complete JV for new US company

Arna Pharma and Slate Run Pharmaceuticals have completed a JV to form a company focusing on branded products and 505(b)(2) medicines. The JV aims to scale the commercialisation of branded and specialised pharmaceutical products for the US market. Arna Pharma provides end-to-end pharmaceutical capabilities. Credit: THICHA SATAPITANON / Shutterstock.com. Arna Pharma and Slate Run Pharmaceuticals have completed a joint venture (JV) to form a speciality pharmaceutical company in the US focusing on branded products, 505(b)(2) medicines, and specialised generics. The companies are also launching their first collaboratively developed product, Aridol, and plan to introduce further branded products in the future.…

Source: Pharmaceutical Technology